IDEXX Laboratories, Inc. (NASDAQ:IDXX) Receives Consensus Rating of “Moderate Buy” from Brokerages

IDEXX Laboratories, Inc. (NASDAQ:IDXX) has received a consensus rating of “Moderate Buy” from the ten analysts that are covering the firm, MarketBeat Ratings reports. Three analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $783.3333.

Several equities analysts have recently issued reports on IDXX shares. Piper Sandler reduced their target price on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a research note on Monday, February 9th. Weiss Ratings lowered IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, January 29th. Wall Street Zen downgraded shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th. UBS Group decreased their price objective on shares of IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating for the company in a report on Tuesday, February 3rd. Finally, BTIG Research dropped their target price on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a research report on Tuesday, February 3rd.

Insider Activity at IDEXX Laboratories

In related news, CEO Jonathan Jay Mazelsky sold 23,326 shares of the stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $657.55, for a total value of $15,338,011.30. Following the completion of the transaction, the chief executive officer directly owned 83,606 shares of the company’s stock, valued at $54,975,125.30. This represents a 21.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP George Fennell sold 11,345 shares of the firm’s stock in a transaction dated Tuesday, February 10th. The stock was sold at an average price of $646.72, for a total transaction of $7,337,038.40. Following the completion of the sale, the executive vice president owned 9,823 shares of the company’s stock, valued at $6,352,730.56. This trade represents a 53.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 45,957 shares of company stock valued at $29,862,109 over the last three months. Corporate insiders own 0.98% of the company’s stock.

Institutional Investors Weigh In On IDEXX Laboratories

Several hedge funds have recently made changes to their positions in the company. Empowered Funds LLC lifted its position in IDEXX Laboratories by 6.6% during the first quarter. Empowered Funds LLC now owns 1,538 shares of the company’s stock valued at $646,000 after buying an additional 95 shares during the period. Sivia Capital Partners LLC purchased a new stake in shares of IDEXX Laboratories in the 2nd quarter worth about $265,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of IDEXX Laboratories in the 2nd quarter worth about $520,000. Foundations Investment Advisors LLC increased its stake in shares of IDEXX Laboratories by 38.9% in the 2nd quarter. Foundations Investment Advisors LLC now owns 914 shares of the company’s stock worth $490,000 after acquiring an additional 256 shares in the last quarter. Finally, Cetera Investment Advisers lifted its position in IDEXX Laboratories by 6.3% during the 2nd quarter. Cetera Investment Advisers now owns 20,643 shares of the company’s stock valued at $11,072,000 after acquiring an additional 1,223 shares during the period. 87.84% of the stock is currently owned by institutional investors.

IDEXX Laboratories Stock Down 1.7%

NASDAQ IDXX opened at $577.12 on Thursday. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.23 and a quick ratio of 0.90. The stock has a market capitalization of $45.89 billion, a PE ratio of 44.16, a PEG ratio of 3.56 and a beta of 1.66. IDEXX Laboratories has a 1 year low of $356.14 and a 1 year high of $769.98. The business’s 50-day moving average is $651.11 and its 200 day moving average is $665.40.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Monday, February 2nd. The company reported $2.92 EPS for the quarter, missing analysts’ consensus estimates of $2.93 by ($0.01). IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The business had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same period in the previous year, the company earned $2.53 EPS. The company’s revenue for the quarter was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Sell-side analysts forecast that IDEXX Laboratories will post 11.93 earnings per share for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.